Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)

Brain Science Institute, NeuroTranslational Drug Discovery Program (K.M.W.,Y.W., C.R., T.T., B.S.S.), and Departments of Neurology (R.R., T.T., B.S.S.) and Psychiatry (B.S.S.), The Johns Hopkins School of Medicine, Baltimore, Maryland; Eisai Inc., Baltimore, Maryland (K.M.W., Y.W., R.L., C.R., T.T., B.S.S.); Parexel International, Waltham, Massachusetts (J.J.V.); and Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland (R.L.)